Pediatric Dermatology

Catch up on all of our coverage from this year's Society for Pediatric Dermatology annual meeting.

A panel at SPD 2026 emphasized how pediatric dermatologists tackle pay gaps using RVU benchmarks, private practice options, and coding tactics to raise reimbursement.

Live from SPD 2026; learn how dermatologists can spot teen body dysmorphia, avoid reassurance traps, and use quick in-clinic tools to trigger early mental health referral.

Honored with a top pediatric dermatology award, Amy Paller, MD, MS, shares her mentorship roots, career highlights, and continued advocacy for new treatments and research.

Sarah Chamlin, MD, and Jonathan Dyer, MD, shared practical guidance on treating ulcerated infantile hemangiomas and assessing café-au-lait spots, emphasizing pain control, propranolol, follow-up, and genetics.

In his session at SPD, Markus Boos, MD, PhD showed how inclusive language, privacy, and team training improve dermatologic care and outcomes for gender minority youth.

At SPD 2026, Brandi Kenner-Bell, MD, FAAD, shared practical pediatric dermatology tips for curly and coily hair: cleanse smarter, deep condition, avoid damaging chemicals, and reduce braid tension to prevent breakage.

Pediatric dermatology experts will gather in Minneapolis for SPD's Annual Meeting: will you be there?

TRAPEDS-1 met its primary pharmacokinetic objective in children aged 6 to 11 years with moderate to severe atopic dermatitis, with no new safety signals over up to 172 weeks of tralokinumab treatment.

Recapping 5 practice-changing FDA decisions from the first half of 2026, including icotrokinra, expanded pediatric indications, and more!

The FDA accepted Arcutis' supplemental NDA seeking to expand roflumilast cream 0.05% to infants aged 3 months to younger than 2 years with mild to moderate AD.

Christopher Bunick, MD, PhD, discusses the FDA's expanded approval of roflumilast cream 0.3% for plaque psoriasis in children as young as 2 years of age.

The approval expands the existing indication for adults and children down to age 6, includes intertriginous areas, and removes restrictions on duration of use.

Andrew Krakowski, MD, encourages involving both caregivers and children in treatment decisions, giving young patients a sense of ownership that can significantly improve adherence.

Verrica Pharmaceuticals and Japanese partner Torii Pharmaceutical have each dosed a first patient in COVE-3, the second pivotal phase 3 trial testing Ycanth for common warts.

Peter Lio, MD, explains how shared decision-making and newer nonsteroidal topicals and systemic options are reshaping pediatric eczema care, easing steroid worries.

Explore evolving pediatric atopic dermatitis care: personalized, stepwise therapy, early-infant treatment gaps, growth monitoring, and expanding nonsteroidal options promising better outcomes.

SkinJect demonstrated 64% clinical clearance and 55% complete histological response in a phase 2 study of nodular BCC patients.

A review in JEADV Clinical Practice argues that deliberate nail examination in children can generate and narrow a differential diagnosis across virtually every organ system.

At 6-month follow-up, no behavioral outcomes — including sunscreen use, hat use, or reapplication — showed statistically significant improvement over baseline levels.

The SWF Clinical Care Network now includes 27 validated US sites assessed objectively for multidisciplinary capacity across dermatology, neurology, ophthalmology, mental health, and transitional care.

Jillian Rork, MD, discusses how Down syndrome is increasingly being understood through the lens of immunology and inflammatory skin disease.

Once-daily roflumilast cream brings fast itch relief, EASI-75 responses, and reassuring safety in 3–24 months, supporting a recent sNDA to the FDA.

Daniel Condie, MD, shares kid-friendly sun safety tips, tanning bed warnings, and early skin cancer detection advice that clinicians can share with families and teens.

Review the latest FDA pediatric dermatology updates, including dupilumab for childhood CSU, secukinumab for teen HS, and new CHE and infant eczema topical filings.